Use of IL-28 and IL-29 to treat cancer and autoimmune disorders

Details for Australian Patent Application No. 2005266892 (hide)

International Classifications

Event Publications

15 February 2007 PCT application entered the National Phase

PCT publication WO2006/012644 Priority application(s): WO2006/012644

8 October 2009 Assignment before Grant

ZymoGenetics, Inc. The application has been assigned to ZymoGenetics, Inc.; Bristol-Myers Squibb Company

3 June 2010 Corrigenda

Assignments Before Grant, Section 113 - 2005 Delete all reference to Application No. 2005266892

3 March 2011 Application Accepted

Published as AU-B-2005266892

31 March 2011 Assignment before Grant

ZymoGenetics, Inc. The application has been assigned to Bristol-Myers Squibb Company; ZymoGenetics, LLC

30 June 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.